Aims: Our current understanding of the pathogenesis of type 1 diabetes (T1D) arose, in large part, from studies using the non-obese diabetic (NOD) mouse model. In the present study, we chose a human-focused method to investigate T1D disease mechanisms and potential targets for therapeutic intervention by directly analysing human donor pancreatic islets from individuals with T1D.
| INTRODUCTION
Type 1 diabetes (T1D) is an autoimmune disorder in which autoreactive T cells target and destroy pancreatic insulin-producing beta cells. This is probably preceded by local inflammation and activation of the innate immune response. 1 Much of our current understanding of T1D pathogenesis arose from studies in non-obese diabetic (NOD) mice. 2 Studies performed in animal models do provide researchers with the ability to manipulate the genetics and physiology of a mammalian system, thereby providing valuable information regarding disease pathogenesis and progression. That said, interventions based on pathways identified to be specifically altered in NOD mice 3, 4 have, up to now, failed in translation to human disease, leading at best to partial stabilization of the insulin secretory capacity of beta cells for short periods of time. 5, 6 Additionally, insulitis is not a uniform pathological feature of the pancreas in human T1D, 7 as it is in NOD mice, and the presence of beta cell mass is evident in many individuals years after onset. 8 Therefore, the direct study of human T1D at various stages of progression may better identify targets that reduce progression or reverse disease. The subsequent manipulation or validation of these targets in mouse models would then provide additional support for moving a candidate toward human clinical study.
There has been increasing evidence recently that beta cells may not be simply bystanders in an autoimmune process, but rather, active players in the progression and pathophysiology of disease. [9] [10] [11] This suggests that an in-depth molecular analysis of human islets from individuals with T1D compared with healthy controls could provide insight into new therapeutic approaches. Here, we present a proof-of-concept study wherein RNA deep sequencing data from the islets of 2 individuals with different T1D disease duration were analysed to parse the changes in gene expression pathways after 3 years of disease (hereafter referred to as "short-duration") compared with 27 years of disease (hereafter referred to as "long-duration") as compared to no disease (non-diabetic control donors). Our data suggest that disease duration impacts the nature of inflammatory pathways activated, and at least 1 pathway (Th1/Th17) displays the potential to be exploited in both humans and NOD mice for the prevention or possible remission of diabetes.
| MATERIALS AND METHODS

| Human islets
Human islets were obtained from deceased organ donors through the
Integrated Islet Distribution Program and Vanderbilt University
(https://iidp.coh.org/Centers/Policies-Standard-OperatingProcedures). Donor characteristics are outlined in Tables S1 and S2. Islet isolations from young donors or donors with long-standing T1D
are not a common occurrence and therefore represent an opportunity to analyse unique aspects of the disease. T1D islets were recovered with good viability (87% and 92%, respectively) and purity (~80%); islets recovered from 3 non-diabetic control donors also showed good viability (95%-96%) and purity (80% to 0%). Shipments of islets were received at the Indiana University School of Medicine (IUSM) and placed into human islet media, which included standard islet media (Prodo Laboratories Aliso Viejo, California), human AB serum supplement (Prodo Laboratories), glutamine and glutathione supplement (Prodo Laboratories) and ciprofloxacin (Fisher Scientific, Pittsburgh, Pennsylvania). All islets were hand-picked to exclude non-islet material and increase purity. RNA was extracted from 200 to 600 islets using the RNeasy Mini Extraction kit (Qiagen, Germantown, Maryland) and equivalent concentrations of RNA from each sample were used for RNA sequencing experiments.
| RNA sequencing
High-depth RNA sequencing was performed using an Illumina HISeq3000 (Indiana University; https://cgb.indiana.edu/sequencing/ index.html), with approximately 239 million paired-end reads obtained per sample. Reads were mapped to the human reference genome GRCh37/hg19 using Tophat 2 12, 13 and Gencode version 18 annotation dataset. 14, 15 Mapped reads were used to quantify gene abundance using the FluxCapacitor program version 1.6.1. 16 All genes were assigned a relative expression level measured in RPKM units ("reads per kilobase per million mapped reads"). 17 The 2 islet samples from T1D donors were analysed and compared separately with control islets. Genes with expression of RPKM >0.5 in at least 1 of the samples studied and with potential pathogenic relevance were identified and reported in the Results section. To define a gene as up-or down-regulated, a cut-off was used of a 3-fold change (FC) compared to the control median expression value. The association of up-or down-regulated genes with molecular/cellular functions and pathways was performed using Ingenu- tis scoring, which was performed as described previously. 20 3 | RESULTS
| Drug studies in NOD mice
| Differential gene expression in human islets from individuals with T1D
Using RNA-sequencing, we characterized differential gene expression in islets isolated from 2 individuals with T1D of vastly different duration. The individual designated as short-duration was 6 years old and had T1D for 3 years, whereas the individual designated as long-duration was 38 years old and had T1D for 27 years. For comparison, we profiled islets from 3 non-diabetic individuals, aged 11, 12 and 64 years (Tables S1 and S2 ). Gene expression patterns from all islet samples were compared with gene expression data from other human tissues collected as part of the Illumina bodyMap2 transcriptome project ( Figure 1 ). Importantly, islet preparations clustered together but were separate from other tissues, indicating that, even with diabetes, the islets retained an "islet identity signature.". Cluster analysis of RNA sequencing data from human tissue samples including human islets with T1D. Gene expression levels were compared for the 5 islet preparations (2 T1D and 3 controls) and 16 background tissues from the Illumina Human Body Map (GEO accession GSE30611). Genes with expression of RPKM >0.5 in at least 1 of the samples, and with potential pathogenic relevance, were considered for analysis. For each pair of samples, a Spearman correlation coefficient (SCC) was computed from the RPKM expression levels. The heatmap shows the clustering dendrograms inferred by employing (1-SCC) as distance function and complete linkage as clustering function, showing both a tight cluster of the 5 islet preparations against the background tissues on one hand and a tight cluster of the 2 T1D samples as compared to the 3 normoglycaemic control samples Expression values for a select group of genes are given in Table 1 (Table 1) . Together, these data confirm a reduction in insulin-expressing beta cells and a possible reduction in differentiated islets cells in both individuals with T1D.
| Pathways altered in T1D
To obtain an unbiased global view of the data, we identified pathways corresponding to collections of genes altered in short-duration or long-duration T1D compared with controls (Table 2; Figure S2 ; Tables S3-S6) . Based on the genes and pathways identified, the software also delineated potential upstream regulators of the up-and down-regulated pathways (Tables S7 and S8 ). Given the reduction in beta cells observed and quantitative loss of hormone gene expression, these down-regulated pathways are probably influenced by altered islet composition.
| Inflammatory genes up-regulated in islets early in disease
The scale of up-regulation (log [B-H P value]) for pathways altered in short-duration T1D was particularly noteworthy and included marked expression of inflammatory-related pathways ( Figure 2 ). "Granulocyte adhesion and diapedesis" was the top canonical pathway increased in short-duration T1D (Table 2) . Additionally, several genes usually expressed in neutrophils, such as CXCL1, CXCL2, CXCL3, CXCL5, CXCL10, CXCL12, CCCL12, CCL3 and CCCL20, and the cytokines IL-1 and IL-8, showed much higher expression in short-duration T1D compared with controls (Table 1 ). These findings suggest that there may exist a protracted infiltration into the islets by innate immune cells such as granulocytes or antigen presenting cells (monocytes/macrophages), along with local production of pro-inflammatory cytokines.
To test this hypothesis we compared the present T1D islet gene expression findings against our previous findings with human islets exposed to the inflammatory cytokines IL-1beta and IFN-gamma. 18 Interestingly, short-duration T1D islets showed a similarity of 36% up-regulated (240 mRNAs) and 37% down-regulated (956 mRNAs) genes compared with cytokine-treated islets; these values were lower in long-duration T1D, namely a similarity of 11% up-regulated (Table S7 ). On the other hand, the upstream regulators of the down-regulated genes were transcription factors related to beta cell function (Table S8) , which is in line with the decrease in insulin expression and beta cells (Table 1 ; Figure S1 ).
| Reduced progression to diabetes with early inhibition of IL-23/p19 in NOD mice
Given the number of altered inflammatory pathways with shortduration T1D, we asked if inhibiting one inflammatory pathway not previously implicated in T1D progression might alter diabetes outcome. Our data identified interleukin 23 alpha subunit p19 (IL23A) and 2 IL-17A pathways (downstream of IL-23) were increased in short-duration T1D, but not in long-duration T1D (Table 1) . This target also proved interesting given its current evaluation as a (p19) in NOD mice early in the course of disease (6 weeks), corresponding to the early stages of insulitis ( Figure 3A) . NOD mice that were treated at 6 weeks of age with anti-IL-23(p19) were followed with weekly blood glucose measurements to determine diabetes onset. Interestingly, treated mice showed significantly reduced progression to diabetes compared with controls (P = .034) Up-and down-regulated pathways identified in short-and long-duration T1D islets. Lists are restricted to top 10 pathways identified for each group. The complete list for each group with additional detail can be found online in Supporting Information Materials. The BenjaminiHochberg adjusted P value for the significance (−Log10 [B-H P value]) used a cutoff of 1.3, which corresponds to > −log10(B-H P value = .05).
The ratio refers to the number of genes in the dataset compared to the total number of genes in the corresponding pathway Ingenuity Pathway Analysis (IPA) for up-regulated genes in canonical pathways identified in short-duration T1D. A total of 667 genes were considered up-regulated in the short-duration T1D sample compared to the samples from normoglycaemic control donors. These genes were subjected to gene set enrichment analysis using the IPA database based on Benjamini-Hochberg corrected Fisher tests. The "canonical pathways" identified by IPA for the upregulated genes in short-duration T1D are displayed. The length of the blue bars indicates the significance of the association between the set of genes and the keyword, and is expressed as minus the logarithm of the probability that a random set of genes from the human genome would be associated with the same keyword. The straight orange line indicates a threshold of 0.05 (corresponding to a −log (B-H P value) of 1.3 on the upper Y-axis). The orange dots for each pathway (connected with a line) indicate the ratio (lower Y-axis) between the number of genes observed in the data set and the total number of genes in the pathway (as annotated in IPA) ( Figure 3B ). Moreover, anti-IL-23(p19) treatment decreased insulitis severity ( Figure 3A ). These data suggest that inhibition of inflammatory pathways identified by functional genomic analysis of human islets from individuals with T1D can alter the course of disease in NOD mice.
| DISCUSSION
Therapeutic interventions derived from pathways first identified to be altered in rodent disease have not effectively translated to interventions in human T1D. We postulate that this is because targets are selected based on a disease pathophysiology specific to NOD mice, which may be different from that of the human disease. Therefore, we proposed the alternative concept of selecting targets for subsequent studies in animal models by first examining the relevant human tissue, in this case pancreatic islets from individuals with T1D. Thus, pancreatic islets from 2 individuals with T1D, where disease duration was vastly different, were analysed. Specifically, we performed functional genomic analysis of islets from donors with short-duration disease (3 years) or long-duration disease (27 years) . When compared to islets from non-diabetic donors, our analysis identified pathways that displayed distinctly different expression patterns between the islets of the 2 T1D donors and between the islets from the T1D donors and non-diabetic controls. This identified, among others, a pathway governed by IL-23(p19), which was selected for further study in NOD mice. We recognize that there are caveats associated with the study of only 2 T1D donors. On the other hand, the treatment of NOD mice early in disease progression with an inhibitor for 1 of these altered human pathways resulted in a significant reduction in disease incidence. Therefore, we believe that the present study underscores the value of using human tissue as the primary point of interrogation, as well as the utility of mouse models to manipulate these human disease-relevant pathways to support possible therapeutic translation.
One of the most distinct differences observed in these data was the up-regulation of innate immunity-related pathways in T1D islets, particularly in short-duration disease. This finding is in line with previously published histology from pancreata of individuals with T1D. 21 Our data are also in line with flow cytometry analysis of islets from the same individual with short-duration T1D (nPOD69), which were subjected to a T cell stimulatory assay that confirmed the presence of CD45+ cells in the islets. 22 Given previous reports that insulitis in human T1D is not uniform and is challenging to observe, 7, 8 an additional interpretation of our data is that the islets themselves express certain genes, particularly chemokines, which influence the recruitment of inflammatory cells to the pancreas early in disease. Given the striking similarity in expression patterns observed in short-duration T1D, which showed more active inflammation, with previous findings in islets exposed to IL-1 beta and IFN-gamma, 18 it is conceivable that these, or other cytokines signaling via similar pathways, are in the islet environment and are relevant for early-stage human disease pathogenesis. These observations are supported by previous studies that identified an "interferon signature" in islets from pancreas biopsies of patients soon after diagnosis of diabetes. anti-IL23(p19) showed that this effect-intervention early in disease progression in NOD mice can significantly influence pathogenesis.
We recognize that using NOD mice permits the manipulation of a target or of pathways earlier in the disease progression than would be possible in humans, as interventions in humans can occur, in most cases, only after the disease is diagnosed. However, identifying an effect at this early stage of disease progression in NOD mice suggests that additional studies to determine the effect at later stages of disease progression in NOD mice are warranted. Ultimately, our study provides proof-of-concept that direct analysis of human islets is valuable for identifying promising targets for effective putative therapeutic interventions in human T1D. Moreover, studies of human Weeks of Age % free of diabetes Anti-IL23 (p19) Control IgG FIGURE 3 Diabetes-free survival of NOD mice treated with or without IL-23/p19 inhibitor. A, Insulitis scoring for NOD mice 6 weeks of age treated with CNTO6163 to block IL23/p19 or isotype control. B, NOD mice treated with CNTO6163 to block IL23/p19 showed significantly reduced diabetes incidence compared with isotype-control treated NOD mice of the same age (P = .034) disease tissue can lead to the repurposing of developed drugs or biologicals, thereby speeding progress toward effective human therapeutics for T1D.
